Roels HA, Lauwerys RR, Buchets JP, Bernard AM, Vos A, Oversteyns M
avoid overtraining during injury recovery phases
His expectations are that within the next three to five years, surgery volumes will return to baseline levels
Comparacin directa entre dos GLP-1 oral ACHIEVE-3 proporciona los primeros datos de comparacin directa entre dos frmacos GLP-1 oral en diabetes tipo 2, en los que orforglipron ha mostrado mayores reducciones de HbA1c y peso que semaglutida oral en las dosis aprobadas para diabetes, afirm el Julio Rosenstock, profesor clnico de Medicina en el Centro Mdico Southwestern de la Universidad de Texas e investigador principal de ACHIEVE-3
You only reach your weight loss goals by combining semaglutide with a healthy lifestyle
Newer agents like serotonin-norepinephrine reuptake inhibitors (SNRIs) similarly present no absolute contraindication to GLP-1 therapy